1. Home
  2. KN vs ADPT Comparison

KN vs ADPT Comparison

Compare KN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knowles Corporation

KN

Knowles Corporation

HOLD

Current Price

$39.00

Market Cap

3.1B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$22.31

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KN
ADPT
Founded
1946
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.7B
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
KN
ADPT
Price
$39.00
$22.31
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$28.00
$17.78
AVG Volume (30 Days)
1.1M
3.7M
Earning Date
04-23-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
118.94
63.89
EPS
0.11
N/A
Revenue
$593,200,000.00
$276,976,000.00
Revenue This Year
$9.40
$3.98
Revenue Next Year
$6.98
$22.72
P/E Ratio
$332.82
N/A
Revenue Growth
7.17
54.77
52 Week Low
$19.28
$9.96
52 Week High
$42.93
$23.15

Technical Indicators

Market Signals
Indicator
KN
ADPT
Relative Strength Index (RSI) 46.98 N/A
Support Level $33.53 N/A
Resistance Level $37.08 N/A
Average True Range (ATR) 1.20 0.00
MACD -0.09 0.00
Stochastic Oscillator 58.73 0.00

Price Performance

Historical Comparison
KN
ADPT

About KN Knowles Corporation

Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: